We are live on ! Find out more
TOVX icon

Theriva Biologics

34 hedge funds and large institutions have $3.32M invested in Theriva Biologics in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,243% more capital inflows, than outflows

Capital inflows: $393K | Capital outflows: $29.2K

300% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 2

26% more funds holding

Funds holding: 27 → 34 (+7)

0.55% more ownership

Funds ownership: 4.93% → 5.48% (+0.55%)

Holders
34
Holders Change
+7
Holders Change %
+25.93%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

TOVX Hedge Fund Activity: Q3 2021 in Review

34 of the 5,733 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2021, worth a combined $3.32M — down 15% from $3.91M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new TOVX positions and 0 closed out — a net gain of 7 holders — while 8 added to existing stakes and 2 trimmed.

The largest buyer was GSA Capital Partners, opening a new position worth an estimated $137K. The largest seller was Virtu Financial, cutting an estimated $28.7K.

  • 34 institutional investors held Theriva Biologics (TOVX) as of Q3 2021, up from 27 in Q2 2021.
  • Funds reported $3.32M of Theriva Biologics stock for Q3 2021, down 15% quarter-over-quarter.
  • 7 funds opened new Theriva Biologics positions in Q3 2021 and 0 closed out, a net change of +7 holders.
  • The largest Theriva Biologics buyer in Q3 2021 was GSA Capital Partners, an estimated $137K added.
  • The largest Theriva Biologics seller in Q3 2021 was Virtu Financial, an estimated $28.7K sold.

Based on aggregated 13F filings for Q3 2021.